CYP1A1 Antibody

What is CYP1A1 and why is it important in research?

CYP1A1 (cytochrome P450, family 1, subfamily A, polypeptide 1) is a member of the cytochrome P450 superfamily of enzymes that plays a crucial role in metabolizing diverse endogenous compounds, such as hormones and fatty acids, as well as xenobiotics, including drugs and environmental toxins. Proper functioning of CYP1A1 is vital for detoxifying harmful substances and maintaining metabolic homeostasis . CYP1A1 is primarily located in the endoplasmic reticulum of liver cells, where it catalyzes substrate oxidation . The importance of CYP1A1 in research stems from its significant role in drug metabolism, toxicology, pharmacogenomics, and personalized medicine. Understanding CYP1A1 expression and regulation provides insights into individual variations in drug response and susceptibility to toxic compounds .

What are the different types of CYP1A1 antibodies available for research?

CYP1A1 antibodies are available in various types with different host species, clonality, and conjugation options:

The selection of the appropriate antibody depends on the specific research application, target species, and experimental design. Monoclonal antibodies offer high specificity for a single epitope, while polyclonal antibodies recognize multiple epitopes and may provide stronger signals in certain applications .

Which applications are CYP1A1 antibodies validated for?

CYP1A1 antibodies have been validated for multiple research applications, with specific optimization for each technique:

When selecting a CYP1A1 antibody for a specific application, researchers should review the validation data provided by the manufacturer and consider the recommended dilutions for optimal results.

How can I optimize Western blot protocols for CYP1A1 detection?

Optimizing Western blot protocols for CYP1A1 detection requires careful consideration of several factors:

• Sample preparation: CYP1A1 is a membrane-associated protein located in the endoplasmic reticulum . Use appropriate lysis buffers containing mild detergents to effectively solubilize the protein while preserving its structure. Consider including protease inhibitors to prevent degradation.

• Protein loading and separation: Load 20-50 μg of total protein per lane and use 8-12% SDS-PAGE gels for optimal separation of CYP1A1 (50-58 kDa) .

• Transfer conditions: Use wet transfer methods with methanol-containing buffers for efficient transfer of hydrophobic proteins like CYP1A1.

• Antibody dilution: Start with the manufacturer's recommended dilution and optimize as needed. For example, antibody 13241-1-AP is recommended to be used at 1:1000-1:4000 dilution for Western blot .

• Positive controls: Include lysates from tissues or cells known to express CYP1A1, such as liver tissue (mouse, rat, human), HepG2 cells, or MCF-7 cells .

• Expected molecular weight: Look for bands between 50-58 kDa, which is the observed molecular weight range for CYP1A1 .

For troubleshooting, consider using longer exposure times if signal is weak, adjusting antibody concentration if background is high, and testing different blocking agents to improve signal-to-noise ratio.

What factors should I consider when choosing between monoclonal and polyclonal CYP1A1 antibodies?

The choice between monoclonal and polyclonal CYP1A1 antibodies depends on several important factors:

How can I validate the specificity of my CYP1A1 antibody?

Validating antibody specificity is crucial for obtaining reliable research results. For CYP1A1 antibodies, consider these methods:

• Positive and negative controls: Use tissues or cell lines with known CYP1A1 expression levels. Liver tissue and HepG2 cells typically express CYP1A1 and can serve as positive controls . Include samples where CYP1A1 is not expressed or is knocked down as negative controls.

• Knockdown/knockout validation: Compare antibody reactivity between wild-type and CYP1A1 knockdown/knockout samples. The 13241-1-AP antibody has been validated in KD/KO applications according to published literature .

• Pre-absorption test: Pre-incubate the antibody with purified CYP1A1 protein before immunostaining. If the antibody is specific, this should eliminate or significantly reduce the signal.

• Multiple antibodies approach: Use different antibodies targeting distinct epitopes of CYP1A1. Consistent results across different antibodies increase confidence in specificity.

• Molecular weight verification: Confirm that the detected band matches the expected molecular weight of CYP1A1 (50-58 kDa) .

• Induction experiments: CYP1A1 expression is inducible by certain compounds. Treatment with known inducers should increase the signal if the antibody is specific.

• Mass spectrometry: Follow immunoprecipitation with mass spectrometry to confirm the identity of the pulled-down protein.

What are the recommended protocols for immunohistochemical detection of CYP1A1?

For optimal immunohistochemical detection of CYP1A1, follow these methodological recommendations:

• Sample preparation: Fix tissues appropriately according to the antibody recommendations. For paraffin-embedded sections, antigen retrieval is often necessary. For 13241-1-AP, suggested antigen retrieval is with TE buffer pH 9.0, although citrate buffer pH 6.0 can be used as an alternative .

• Antibody dilution: Use the recommended dilution range for IHC. For example, 13241-1-AP is recommended at 1:50-1:500 dilution for IHC applications . Always optimize the dilution for your specific tissue and protocol.

• Detection system: Choose an appropriate detection system compatible with the primary antibody host species. DAB (3,3'-diaminobenzidine) is commonly used for visualization.

• Positive controls: Include tissues known to express CYP1A1, such as liver tissue. For 13241-1-AP, positive IHC signals have been detected in human breast cancer tissue .

• Negative controls: Include sections without primary antibody and, if possible, tissues known not to express CYP1A1 or from knockout animals.

• Counterstaining: Use appropriate counterstains such as hematoxylin to visualize tissue architecture without obscuring CYP1A1 staining.

• Interpretation: CYP1A1 should appear primarily in the endoplasmic reticulum, showing cytoplasmic staining patterns in cells expressing this enzyme .

For higher sensitivity in detecting low CYP1A1 expression, consider using amplification systems or fluorescent secondary antibodies with confocal microscopy for better signal resolution and quantification.

How should I design experiments to study CYP1A1 induction?

Designing robust experiments to study CYP1A1 induction requires careful consideration of several methodological aspects:

• Cell/tissue selection: Choose relevant models for your research question. Hepatocytes, hepatoma cell lines (HepG2, HepaRG), or liver tissue slices are commonly used due to their metabolic capacity . Lung tissue and cells also express CYP1A1 and can be appropriate models .

• Inducers: Select appropriate CYP1A1 inducers based on your research question:

  • Classical inducers: TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin), polycyclic aromatic hydrocarbons

  • Dietary compounds: Certain flavonoids, cruciferous vegetable constituents

  • Pharmaceutical compounds: Omeprazole, other AhR ligands

• Exposure conditions: Determine appropriate:

  • Dose ranges (typically establish a dose-response curve)

  • Time points (6-48 hours to capture both early and late induction)

  • Exposure method (dissolved in appropriate vehicle, considering solubility)

• Controls:

  • Vehicle control (matching the solvent used for inducers)

  • Positive control (known CYP1A1 inducer)

  • Negative control (compound known not to induce CYP1A1)

• Detection methods:

  • mRNA expression: RT-PCR or RNA sequencing

  • Protein expression: Western blot with validated antibodies (13241-1-AP at 1:1000-1:4000 dilution )

  • Enzymatic activity: EROD (ethoxyresorufin-O-deethylase) assay

  • Cellular localization: Immunofluorescence (IF/ICC with 13241-1-AP at 1:200-1:800 dilution )

• Data analysis:

  • Normalization to appropriate housekeeping genes/proteins

  • Statistical analysis comparing treated vs. control groups

  • Dose-response modeling if applicable

• Mechanism investigation:

  • AhR pathway involvement (using AhR antagonists or siRNA)

  • Other potential regulatory pathways

This comprehensive approach allows for robust characterization of CYP1A1 induction patterns and mechanisms in your experimental system.

What controls should I include when using CYP1A1 antibodies?

Implementing appropriate controls is essential for generating reliable and interpretable results when using CYP1A1 antibodies:

• Positive tissue/cell controls:

  • Liver tissue (mouse, rat, human) - known to express high levels of CYP1A1

  • HepG2 cells - human hepatocellular carcinoma cell line with detectable CYP1A1

  • MCF-7 cells - breast cancer cell line where PA1-340 has been validated

  • Other validated samples: mouse cerebellum tissue, mouse lung tissue, rat liver tissue

• Negative controls:

  • Primary antibody omission - apply all reagents except the primary antibody

  • Isotype control - use an irrelevant antibody of the same isotype (e.g., IgG2a for B-4 or IgG for polyclonal antibodies )

  • Tissues/cells known to have minimal CYP1A1 expression (or knockout/knockdown samples)

• Specificity controls:

  • Competing peptide/protein blocking - pre-incubate antibody with the immunogen peptide

  • Secondary antibody only - to detect non-specific binding of secondary antibody

  • Multiple antibodies targeting different epitopes - for confirmation of results

• Technical controls:

  • Loading controls for Western blot (β-actin, GAPDH)

  • Staining controls for IHC/IF (nuclear counterstain)

  • Process controls to ensure consistent technique application

• Experimental manipulation controls:

  • CYP1A1 induction - treat cells with known inducers (e.g., TCDD, benzopyrene) to increase expression as a positive control

  • CYP1A1 inhibition - use specific inhibitors or siRNA knockdown to reduce expression

These controls should be systematically incorporated into experimental designs to ensure the validity of results obtained with CYP1A1 antibodies.

How do I interpret varying molecular weights observed for CYP1A1?

Interpreting variations in the observed molecular weight of CYP1A1 requires understanding several factors that can affect protein migration in gel electrophoresis:

• Expected molecular weight range: The calculated molecular weight of CYP1A1 is approximately 58 kDa (512 amino acids) , but the observed molecular weight typically ranges from 50-58 kDa . This variation is normal and can result from multiple factors.

• Post-translational modifications: CYP1A1 can undergo various modifications that affect its migration pattern:

  • Phosphorylation can add approximately 0.5-1 kDa per phosphate group

  • Glycosylation can significantly increase apparent molecular weight

  • Proteolytic processing may result in smaller fragments

• Protein conformation: Incomplete denaturation can result in faster migration than expected.

• Tissue/cell type variations: Different cellular environments may lead to different post-translational modification patterns. For example, CYP1A1 detected in liver tissue might show a slightly different molecular weight than in lung tissue .

• Experimental conditions affecting migration:

  • Gel percentage (higher percentage gels can compress bands)

  • Running buffer composition

  • Applied voltage and duration

• Isoform detection: The antibody may detect other closely related P450 isoforms, as noted for PA1-340 , which could appear as bands of slightly different molecular weights.

If you observe unexpected molecular weight variations, consider:

• Running known positive controls alongside your samples

• Using gradient gels for better resolution

• Confirming identity through mass spectrometry or using multiple antibodies targeting different epitopes

What approaches can I use to quantify CYP1A1 expression levels?

Several approaches can be employed to quantify CYP1A1 expression levels, each with specific advantages:

• Western blot quantification:

  • Use appropriate loading controls (β-actin, GAPDH, total protein staining)

  • Employ a standard curve with recombinant CYP1A1 protein

  • Use densitometry software to measure band intensity

  • Recommended antibody dilutions: 1:1000-1:4000 for 13241-1-AP

  • Ensure you are in the linear range of detection

• Immunohistochemistry quantification:

  • Use digital image analysis software to quantify staining intensity

  • Score by percentage of positive cells and intensity of staining

  • Include calibration standards in each experiment

  • Recommended antibody dilutions: 1:50-1:500 for 13241-1-AP in IHC applications

• Flow cytometry:

  • Measure mean fluorescence intensity of labeled cells

  • Use appropriate negative and positive controls

  • Recommended antibody concentration: 0.25 μg per 10^6 cells for intracellular staining with 13241-1-AP

  • Analyze shifts in population distributions

• ELISA:

  • Develop a standard curve using recombinant CYP1A1

  • Optimize antibody concentrations and blocking conditions

  • Multiple antibodies (sc-25304, 13241-1-AP) are validated for ELISA applications

• RT-qPCR for mRNA quantification:

  • Design specific primers for CYP1A1

  • Use appropriate reference genes for normalization

  • Compare with protein levels when possible (as mRNA and protein levels may not always correlate)

• Enzyme activity assays:

  • EROD (ethoxyresorufin-O-deethylase) assay to measure CYP1A1 activity

  • Correlate activity with protein expression determined by antibody-based methods

For all quantification methods, include appropriate controls and perform statistical analysis to ensure the significance of observed differences in expression levels.

How do I analyze CYP1A1 localization data from immunofluorescence experiments?

Analyzing CYP1A1 localization data from immunofluorescence experiments requires systematic approaches to ensure accurate interpretation:

• Expected localization pattern: CYP1A1 is primarily located in the endoplasmic reticulum , so anticipate a cytoplasmic, reticular staining pattern that may concentrate in perinuclear regions but should be absent from the nucleus.

• Co-localization studies:

  • Use markers for subcellular compartments (e.g., calreticulin or PDI for endoplasmic reticulum)

  • Apply appropriate fluorescent secondary antibodies with non-overlapping emission spectra

  • Calculate co-localization coefficients (Pearson's, Mander's, etc.) using image analysis software

• Image acquisition considerations:

  • Use optimal antibody dilutions (1:200-1:800 for 13241-1-AP in IF/ICC )

  • Capture multiple z-stacks for three-dimensional analysis

  • Include positive controls (HeLa cells for 13241-1-AP )

  • Use consistent exposure settings across experimental conditions

• Quantitative analysis approaches:

  • Intensity measurements across defined cellular regions

  • Line scan analysis to demonstrate distribution patterns

  • Measurement of signal-to-background ratios

  • Analysis of co-localization coefficients with organelle markers

• Advanced analysis techniques:

  • Super-resolution microscopy for detailed localization

  • FRET (Fluorescence Resonance Energy Transfer) for protein interaction studies

  • Live-cell imaging with tagged CYP1A1 to monitor dynamic localization

  • Fluorescence recovery after photobleaching (FRAP) to study mobility

• Interpreting changes in localization:

  • Upon induction, evaluate whether increased expression maintains the same localization pattern

  • Assess potential redistribution under stress conditions

  • Determine if mutations or truncations affect localization

• Common artifacts to watch for:

  • Overexpression artifacts in transfected cells

  • Fixation-induced changes in localization

  • Autofluorescence (particularly in tissues with high lipid content)

  • Non-specific antibody binding

By following these approaches, researchers can accurately analyze and interpret CYP1A1 localization data from immunofluorescence experiments, gaining insights into the protein's subcellular distribution and potentially altered localization under various experimental conditions.

How can I differentiate between CYP1A1 and closely related P450 isoforms?

Differentiating between CYP1A1 and closely related P450 isoforms (particularly CYP1A2) requires strategic experimental approaches:

• Antibody selection:

  • Choose antibodies raised against unique epitopes of CYP1A1

  • Review cross-reactivity data provided by manufacturers

  • For example, PA1-340 is noted to detect other P450 isoforms to a lesser extent

  • Consider using antibodies targeting the C-terminal region, which often differs between isoforms

• Validation techniques:

  • Western blot with recombinant CYP1A1 and related isoforms

  • Immunoprecipitation followed by mass spectrometry identification

  • Testing in knockout/knockdown systems for each specific isoform

  • Pre-absorption tests with specific peptides

• Expression pattern analysis:

  • CYP1A1 is primarily extrahepatic and highly inducible

  • CYP1A2 is predominantly expressed in liver and less inducible

  • Compare expression patterns in different tissues (lung vs. liver)

• Substrate specificity assays:

  • Use selective substrates (e.g., 7-ethoxyresorufin for CYP1A1)

  • Apply selective inhibitors in activity assays

  • Compare with genetic knockdown results

• Induction profiles:

  • CYP1A1 is typically more responsive to AhR ligands than CYP1A2

  • Use time-course and dose-response studies to differentiate induction patterns

• Molecular techniques:

  • RT-PCR with isoform-specific primers

  • RNA-Seq analysis for transcript-level discrimination

  • CRISPR-Cas9 targeting of specific isoforms followed by antibody testing

By combining these approaches, researchers can more confidently distinguish CYP1A1 from related P450 isoforms, ensuring the specificity of their experimental results and interpretations.

What are common issues when working with CYP1A1 antibodies and how can I troubleshoot them?

Working with CYP1A1 antibodies can present several challenges. Here are common issues and troubleshooting strategies:

• Weak or no signal in Western blot:

  • Increase antibody concentration (try 1:1000 if 1:4000 shows no signal)

  • Extend exposure time

  • Check protein loading (50-58 kDa band expected)

  • Use fresh tissue/cell lysates (CYP1A1 can degrade during storage)

  • Verify transfer efficiency with reversible staining

  • Consider using enhanced chemiluminescence detection systems

• High background in immunohistochemistry/immunofluorescence:

  • Optimize antibody dilution (start with 1:200-1:800 for IF/ICC or 1:50-1:500 for IHC)

  • Increase blocking time/concentration

  • Try different blocking agents (BSA, normal serum, commercial blockers)

  • Include additional washing steps

  • Test different fixation methods

• Cross-reactivity with other P450 isoforms:

  • Use antibodies targeting unique epitopes

  • Include appropriate controls (tissues from knockout animals)

  • Validate with multiple antibodies targeting different epitopes

  • Consider pre-absorption with purified proteins

• Inconsistent results between experiments:

  • Standardize protocols rigorously

  • Prepare fresh working solutions of antibodies

  • Monitor storage conditions (store at -20°C in recommended buffer)

  • Include consistent positive controls in each experiment

  • Use the same lot number when possible for critical experiments

• Discrepancy between mRNA and protein levels:

  • Check for post-transcriptional regulation

  • Assess protein stability/degradation

  • Examine sampling timepoints (protein expression may lag behind mRNA)

• Poor reproducibility in quantitative analysis:

  • Standardize image acquisition settings

  • Use internal calibration standards

  • Apply consistent analysis protocols

  • Increase biological and technical replicates

• Issues with specific applications:

  • Flow cytometry: Ensure proper permeabilization for this intracellular protein

  • IP: Use higher antibody amounts (0.5-4.0 μg for 1.0-3.0 mg total protein)

  • IHC: Try different antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0)

Methodical troubleshooting and optimization are essential for obtaining reliable results with CYP1A1 antibodies across different experimental applications.

How do environmental factors affect CYP1A1 expression and antibody detection?

Environmental factors can significantly influence CYP1A1 expression and consequently affect antibody detection results:

• Induction by xenobiotics:

  • Polycyclic aromatic hydrocarbons (PAHs) strongly induce CYP1A1 via AhR activation

  • Dioxins and dioxin-like compounds are potent inducers

  • Cigarette smoke exposure increases CYP1A1 expression

  • Consider previous exposures of test subjects/samples

• Dietary factors:

  • Cruciferous vegetables contain compounds that induce CYP1A1

  • Flavonoids can modulate expression levels

  • Fasting conditions may alter basal expression

  • Control for dietary variables in experimental design

• Cell culture conditions affecting detection:

  • Serum components may contain AhR ligands

  • Plastic leachates can activate AhR pathways

  • Cell density affects expression levels

  • Oxygen tension influences CYP enzyme activity

  • Media composition may affect background in immunoassays

• Sample handling considerations:

  • Time between sample collection and processing

  • Freeze-thaw cycles can degrade protein

  • Fixation methods for tissues affect epitope accessibility

  • Storage conditions influence protein stability

• Physiological factors:

  • Circadian rhythm affects CYP1A1 expression

  • Hormonal status influences regulation

  • Inflammatory conditions can alter expression

  • Age-related changes in expression and regulation

• Experimental design recommendations:

  • Include appropriate vehicle controls

  • Monitor baseline expression levels

  • Document exposure history when possible

  • Standardize sample collection and processing

  • Consider time-course experiments to capture induction dynamics

• Antibody detection optimization:

  • For induced samples, adjust antibody dilutions accordingly

  • Include gradient of positive controls (untreated and induced)

  • For samples with expected low expression, consider signal amplification methods

  • When comparing across environments, process all samples simultaneously

Understanding these environmental influences is crucial for accurate interpretation of CYP1A1 antibody detection results and for designing experiments that control for these variables appropriately.

What are the emerging applications of CYP1A1 antibodies in research?

CYP1A1 antibodies continue to evolve as valuable tools in various cutting-edge research areas:

• Precision medicine and pharmacogenomics:

  • Characterizing individual variations in CYP1A1 expression to predict drug metabolism patterns

  • Correlating genotype with protein expression using specific antibodies

  • Developing personalized dosing strategies based on CYP1A1 expression profiles

  • Investigating ethnic differences in CYP1A1 expression and function

• Environmental toxicology:

  • Biomonitoring CYP1A1 induction as a biomarker for exposure to environmental pollutants

  • Assessing tissue-specific responses to xenobiotics

  • Developing high-throughput screening systems for potential toxicants

  • Studying long-term adaptive responses to environmental stressors

• Cancer research:

  • Investigating CYP1A1's role in procarcinogen activation

  • Characterizing CYP1A1 expression in different tumor types

  • Correlating expression with treatment response and prognosis

  • Exploring CYP1A1 as a therapeutic target in certain cancers

• Single-cell analysis:

  • Applying CYP1A1 antibodies in mass cytometry (CyTOF)

  • Characterizing cell-specific expression patterns in heterogeneous tissues

  • Combining with other markers to identify specialized metabolic populations

  • Mapping CYP1A1 expression in spatial transcriptomics/proteomics

• Advanced imaging technologies:

  • Super-resolution microscopy to study subcellular localization

  • Multiplexed immunofluorescence for pathway analysis

  • Intravital imaging to monitor real-time CYP1A1 induction

  • Correlative light and electron microscopy to study ultrastructural context

• 3D models and organoids:

  • Characterizing CYP1A1 expression in liver and lung organoids

  • Validating metabolic functionality of engineered tissues

  • Developing physiologically relevant drug testing platforms

  • Studying zone-specific expression in 3D culture systems

These emerging applications highlight the continued importance of high-quality, well-characterized CYP1A1 antibodies in advancing our understanding of xenobiotic metabolism, toxicology, and precision medicine approaches.

What resources are available for researchers working with CYP1A1 antibodies?

Researchers working with CYP1A1 antibodies can access various resources to enhance their experimental design and interpretation:

• Antibody validation databases:

  • Antibodypedia (www.antibodypedia.com)

  • Antibody Registry (antibodyregistry.org)

  • CiteAb (www.citeab.com)

  • Manufacturer validation data from Santa Cruz, Proteintech, Thermo Fisher, and others

• Methodology repositories:

  • Journal of Visualized Experiments (JoVE) for video protocols

  • Bio-protocol for peer-reviewed protocols

  • Protocols.io for community-shared methodologies

• Reference materials:

  • Recombinant CYP1A1 proteins as positive controls

  • Characterized cell lines with known CYP1A1 expression levels

  • CYP1A1 knockout/knockdown systems for specificity testing

• Online tools:

  • PhosphoSitePlus for information on post-translational modifications

  • Protein Atlas for tissue expression patterns

  • UniProt for sequence and structure information

  • ExPASy for computational tools to analyze protein properties

• Research networks and communities:

  • Drug Metabolism Discussion Group (DMDG)

  • International Society for the Study of Xenobiotics (ISSX)

  • Environmental Mutagenesis and Genomics Society (EMGS)

• Published literature resources:

  • Review articles on CYP1A1 structure, function, and regulation

  • Method papers describing optimized protocols

  • Validation studies comparing different antibodies

  • Meta-analyses of CYP1A1 expression across tissues and conditions

• Technical support:

  • Manufacturer technical services for troubleshooting

  • Application notes specific to CYP1A1 detection

  • Webinars and training videos on antibody techniques

By leveraging these resources, researchers can optimize their experimental approaches, validate their findings, and contribute to the growing body of knowledge about CYP1A1 biology and its implications in drug metabolism, toxicology, and disease.